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Abstract
Background: Prescribing of antibiotics for upper respiratory tract infections (URTI) varies substantially in primary care.
Objectives: To describe and compare antibiotic and antipyretic/anti-inflammatory drugs use, URTI symptoms’ resolution
and occurrence of potentially-associated infections in patients seeking care from general practitioners (GPs) who exclusively
prescribe conventional medications (GP-CM), regularly prescribe homeopathy within a mixed practice (GP-Mx), or are
certified homeopathic GPs (GP-Ho).
Method: The EPI3 survey was a nationwide population-based study of a representative sample of 825 GPs and their patients
in France (2007–2008). GP recruitment was stratified by self-declared homeopathic prescribing preferences. Adults and
children with confirmed URTI were asked to participate in a standardized telephone interview at inclusion, one-, three- and
twelve-month follow up. Study outcomes included medication consumption, URTI symptoms’ resolution and potentially-
associated infections (sinusitis or otitis media/externa) as reported by patients. Analyses included calibration to account for
non-respondents and groups were compared using multivate analyses adjusting for baseline differences with a propensity
score.
Results: 518 adults and children with URTI (79.3% rhinopharyngitis) were included (36.9% response rate comparable
between groups). As opposed to GP-CM patients, patients in the GP-Ho group showed significantly lower consumption of
antibiotics (Odds ratio (OR) = 0.43, 95% confidence interval (CI): 0.27–0.68) and antipyretic/anti-inflammatory drugs
(OR= 0.54, 95% CI: 0.38–0.76) with similar evolution in related symptoms (OR = 1.16, 95% CI: 0.64–2.10). An excess of
potentially-associated infections (OR= 1.70, 95% CI: 0.90–3.20) was observed in the GP-Ho group (not statistically
significant). No difference was found between GP-CM and GP-Mx patients.
Conclusion: Patients who chose to consult GPs certified in homeopathy used less antibiotics and antipyretic/anti-
inflammatory drugs for URTI than those seen by GPs prescribing conventional medications. No difference was observed in
patients consulting GPs within mixed-practice. A non-statistically significant excess was estimated through modelling for
associated infections in the GP-Ho group and needs to be further studied.
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Introduction
High antibiotic consumption is said to be associated with the
emergence and dissemination of multi-resistant bacteria in the
community [1]. Demands and expectations for antibiotics in
common upper respiratory tract infections [URTI]) are important
drivers of antibiotic overprescribing in primary care [2]. Many
countries have initiated programs targeted at physicians and the
general public to reduce antibiotic prescribing [3]. Most evaluated
programs have recorded some success even though the effect on
resistance to antimicrobial drugs, and particularly on dissemina-
tion of antibiotic-resistant pneumococci, remains uncertain [4].
Substantial heterogeneity in antibiotic prescribing among French
GPs has been observed [5]. Despite the modest decrease in
ambulatory antibiotic prescribing for respiratory tract infections
between 2001 and 2009, France remains a country with one of the
highest antibiotic consumption rates in Europe [6,7].
While there is evidence that homeopathy has little effect on
URTI or flu-like symptoms [8,9], its potential for reducing
antibiotic consumption has been proposed [10]. In France,
homeopathic medicines are partially reimbursed by the National
Health Insurance and are prescribed exclusively by a physician.
Besides, patients must choose a ‘treating physician’, who will be
responsible for follow-up and referral to specialists. This treating
physician may be a physician specializing in homeopathy. This
context provided a unique opportunity to observe homeopathic
prescribing practices in the management of patients with URTI in
primary care.
The objectives of this one-year population-based cohort study
was to describe and compare antibiotic and antipyretic/anti-
inflammatory drugs use, resolution of URTI symptoms and
occurrence of potentially associated infections in patients who seek
care for URTI from general practitioners (GPs) showing different
prescribing preferences for homeopathy: strictly prescribers of
conventional medications reluctant to prescribe homeopathic
medicines (GP-CM), regular prescribers of homeopathic medicines
in an otherwise conventional medical practice (‘‘mixed prescrib-
ing’’ or GP-Mx), and certified homeopathic GPs (GP-Ho), who
also prescribe conventional medications.
Methods
Study design and population
The EPI3 survey was a nationwide survey of primary care
practice conducted in a representative sample of GPs from across
France and their patients between 2007 and 2008 [11]. The
sample was drawn using a two-stage sampling process. First, a
random sample of GPs was drawn from the French national
directory of physicians in primary care. Sampling of GPs was
stratified according to self-declaration of prescribing preferences
obtained by telephone at the time of recruitment and categorized
into three groups: strictly prescribers of conventional medications
(GP-CM) who declared never using homeopathy, or only at the
patient’s request; regular prescribers of homeopathic medicines
within a mixed prescribing practice (GP-Mx); and certified
homeopathic GPs (GP-Ho). Second, a one-day survey of all
patients attending the medical practice of each participating GP
was conducted where a trained research assistant surveyed all
patients in the waiting room. For this cohort study, the first 5
(minimum) to 15 (maximum) consenting adult patients and
guardians of children were invited to participate if (a) the
attending physician was declared by patients as their regular
physician (designated ‘‘treating physician’’ according to French
regulation) and (b) one of the clinical diagnosis declared by the
physician at that visit included one of the following ICD-9
(International Classification of Diseases 9th revision) [12] codes:
acute nasopharyngitis [common cold] (code 460), acute upper
respiratory infections of multiple or unspecified sites (code 465);
acute bronchitis and bronchiolitis or bronchitis, not otherwise
specified (codes 466 and 490, respectively), acute pharyngitis (code
462) and acute laryngitis and tracheitis (code 464).
Data collection
At inclusion, GPs completed a medical questionnaire for each
patient included in the cohort with the main reason diagnosis, a
standardized history of respiratory diagnoses in the previous year
and of respiratory symptoms in the current episode of URTI, up to
five other diagnoses (comorbidities) and all drugs prescribed that
day. Diagnoses were coded according to the ICD-9 classification
by a trained research assistant. All consenting patients completed a
self-administered questionnaire at inclusion, in the waiting room,
collecting information on lifestyle and history of medical consul-
tations and hospitalizations in the previous year. The follow-up
telephone interview at one month included the inventory of URTI
symptoms obtained via patients’ self-assessment of changes in
those symptoms from baseline (cleared, much improved, slightly
improved, no change or worsened). Interviews at one, three and
twelve months spanned the patient’s history since the previous
interview with regard to the occurrence of infections associated
with the URTI, defined as patients’ self-report of a diagnosis (with
or without treatment) of otitis (media or externa) and/or sinusitis,
and any drug consumption (conventional and homeopathy). This
calendar was used to aid patients’ recall during the one-year
follow-up. Drug consumption, whether prescribed or obtained
over-the-counter or from the family pharmacy, was assessed using
a standardized method named Progressive Assisted Backward
Active Recall (PABAR) previously validated against medical
prescriptions [13,14]. Briefly, patients received at the time of their
recruitment a booklet detailing the interview, including a list of
commonly used drugs for URTIs, and were instructed to collect all
their prescriptions. Trained interviewers helped patients recall past
exposure to drugs, starting with recent history and progressing
back in time to identify events at key dates. Drugs were
automatically recorded using the anatomical therapeutic chemical
classification index (ATC), 2009 revision. Particular emphasis was
put on antibiotics [antibacterial for systemic use (class J01),
neuraminidase inhibitors (class J05AH)], antipyretics [acetamino-
phen (class N02BE01), acetylsalicylic acid (class N02BA01)] and
non-steroidal anti-inflammatory drugs (NSAIDs) [ibuprofen (class
M01AE01)], as well as homeopathic drugs commonly used in
URTI. Patients were asked to specifically report consumption of
any drug from a list of 41 products after they had spontaneously
reported all drugs used. Patients also reported the occurrence of
diagnoses (with or without treatment) of otitis (media or externa)
and/or sinusitis. Those two diagnoses were used as proxies for
potentially associated infections.
Study outcomes
Four outcomes were evaluated as yes/no responses (Table 1).
Consumption of antibiotics and antipyretic/anti-inflammatory
drugs for URTI was defined at each interview interval as the
proportion of patients who declared using at least one drug (since
the previous interview) from any of the ATC classes listed above.
Utilization of antibiotics and antipyretic/anti-inflammatory drugs
was then defined as at least one utilization for URTI at any of the
one, three or twelve-month interviews. Resolution of the URTI
EPI3 Study on Homeopathy and Antibiotics for URTI
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was defined following either patients’ self-report of complete
resolution or significant improvement of baseline symptoms at the
one-month interview. Infections potentially associated to the
URTI were defined following patients’ self-report of at least one
declaration of a diagnosis of otitis media, otitis externa or sinusitis
(with or without treatment) at any of the one, three or twelve-
month interviews.
Statistical analysis
Participants and nonparticipants in the cohort study were
compared using information collected from all surveyed patients at
baseline. Characteristics of patients not participating in the survey
(gender, age and main reasons for consultation) were used to
calibrate the final sample using a method known as the CALMAR
procedure [15]. In this method, differences between participants
and nonparticipants were compensated by attributing a specific
weight to each patient in the analysis, inversely proportional to the
participation rate of similar patients at baseline among all patients
surveyed. Differences at baseline between GP-CM, GP-Mx and
GP-Ho groups were estimated using multivariate logistic regres-
sion analyses. A propensity score was computed for each
participant in the study indicating their probability of belonging
to either GP-Mx or GP-Ho groups compared to the GP-CM
group according to all variables listed in Table 2. The score was
Table 1. Comparison of drug utilization, resolution of URTI symptoms and occurrence of potentially associated infections among
types of medical practice1.
Odds ratio¥ [95% confidence interval] (number of events)
GP-CM (N=165) GP-Mx (N=203) GP-Ho (N=150)
Drug utilization
Antibiotic use (Used at least once for URTI in 12 months) 1.00 (75) 1.07 [0.79–1.46] (91) 0.43 [0.27–0.68] (27)
Antipyretic/anti-inflammatory drug use
(Used at least once for URTI in 12 months)
1.00 (106) 1.23 [0.91–1.65] (126) 0.54 [0.38–0.76] (61)
Resolution of the URTI Symptoms resolved or
greatly improved (Self-declaration at 1 month)
1.00 (110) 1.10 [0.63–1.91] (141) 1.16 [0.64–2.10] (104)
Potentially associated infections
(At least one declaration of otitis/sinusitis in 12 months)
1.00 (24) 0.88 [0.46–1.71] (23) 1.70 [0.90–3.20] (32)
1Type of medical practice according to physicians’ prescribing preferences: GP-CM, conventional medicine used as the category of reference; GP-Mx, mixed prescribing
practice (conventional and homeopathic); GP-Ho, registered homeopathic physicians.
¥Odds ratios and 95% confidence intervals obtained by logistic regression using GEE models adjusted for all variables in Tables 2 and 3.
doi:10.1371/journal.pone.0089990.t001
Table 2. Baseline characteristics of patients with upper respiratory tract infections (URTI) by type of medical practice1.
Total GP-CM GP-Mx GP-Ho Nonparticipating patients
N=518 (%) N=165 (%) N=203 (%) N=150 (%) N=884 (%)
Female gender 59.8 58.2 58.6 63.3* 54.2¥
Age (years)
0–19 41.9 38.2 43.3 44.0 40.5
20–49 33.6 41.2 29.1 31.3 39.7
50+ 24.5 20.6 27.6 24.7 19.8¥
High school degree
completed (adults only)
57.1 55.7 50.8 65.7* 53.4¥
Body Mass Index (adults only)
,25 60.6 65.0 51.3 68.3 61.9
25+ 39.4 35.0 48.7 31.7 38.1
Smoking (adults only)
Non smoker 47.3 36.4 50.2 55.3* 39.6
Former smoker (.1 year) 23.0 27.9 20.7 20.7 21.4
Current smoker or recent
smoker (,1 year)
29.7 35.7 29.1 24.0 39.0¥
Physical activity $30 minutes
per day (adults only)
28.1 33.5 25.7 25.5 29.7
1Type of medical practice according to physicians’ prescribing preferences: GP-CM, conventional medicine; GP-Mx, mixed practice (conventional and homeopathic); GP-
Ho, registered homeopathic physicians.
¥Differences compared to participants statistically significant (p,0.05).
*Differences compared to the GP-CM group statistically significant (p,0.05).
doi:10.1371/journal.pone.0089990.t002
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intended to adjust for confounding by differences between the
groups in all subsequent analyses.
The three groups were compared for the four binary outcomes
using the GP-CM group as the reference group using logistic
regression analyses adjusted for baseline characteristics (propensity
score) and the number of URTI symptoms at baseline (as listed in
Table 3). Clustering effects resulting from recruiting several
patients consulting the same GP and autocorrelation between
responses to the four consecutive interviews were controlled using
Generalized Estimating Equations (GEE) in the multivariate
models. Sample size was estimated for the EPI3 survey as a whole
so as to provide accurate estimates of prevalence (at62%) for each
group of diagnoses seen in primary care, including URTI. All
analyses were performed using SAS version 9.1 (SAS Institute,
Inc., Cary, North Carolina).
Ethics Statement
The study was approved by the French National Data-
Protection Commission (CNIL) and the French National Medical
Council (CNOM). In accordance with CNIL regulation, written
consent was obtained from each participating adult patient and
from one of the parents accompanying each participating child.
Participating physicians received compensation fees for their
participation but not patients.
Results
The general EPI3 health survey included 825 GPs and 8,559
participants (ten patients per GP on average, minimum 5,
maximum 15). Of the latter, 1,402 children and adults fulfilled
the specific inclusion criteria for the URTI cohort, of which 699
(49.9%) agreed to participate with 518 (36.9%) responding to all
three follow-up interviews and therefore included in the analysis.
Participants were slightly more often females (59.8%) compared to
nonparticipants (54.2%), more likely to belong to the 50+ years
age group (24.5% and 19.8%, respectively), to have completed
high school education (57.1% and 53.4%), and less likely to be a
current smoker (29.7% and 39.0%, respectively), all differences
statistically significant (Table 2). Of participants under 20 years of
age (41.9%), two thirds (28.1%) were 6 years old or younger.
Among participants, patients who consulted a GP-Ho were more
often non-smoking females who completed high school education
compared to the GP-CM group, differences that were statistically
significant after taking into account all other factors, and were
similar otherwise (Table 2). Patients in the GP-Mx group were
comparable to the GP-CM group.
With regard to types of URTI at baseline, there were little
differences between the three groups. The most commonly
reported was rhinopharyngitis (73.9%), followed with bronchitis
(28.0%), flu-like symptoms (12.7%), Strep-A negative viral angina
(8.7%) and bronchiolitis (5.2%) (Table 3). For symptoms reported
by patients, those who consulted a GP-Ho were less likely to have
Table 3. Baseline clinical characteristics of upper respiratory tract infections (URTI) by type of medical practice1.
Total GP-CM GP-Mx GP-Ho
N=518 (%) N=165 (%) N=203 (%) N=150 (%)
URTI symptoms at inclusion
Fever $38.5uC 51.0 53.3 59.1 37.3*
Rhinorrhea 72.4 75.2 71.4 70.7
Nasal obstruction 57.3 63.0 56.2 52.7*
Cough 71.2 76.4 72.4 64.0*
Shortness of breath 30.1 27.9 36.5 24.0
Dysphagia 21.8 22.4 23.6 18.7
Stomatitis 4.1 3.6 5.9 2.0
Diagnoses/syndrome at inclusion
Rhinopharyngitis 73.9 75.2 70.9 76.7
Bronchitis 28.0 29.1 31.5 22.0
Bronchiolitis 5.2 6.1 5.4 4.0
Flu-like symptoms 12.7 10.9 14.8 12.0
Viral angina (negative Strep-A rapid test) 8.7 9.1 9.9 6.7
Comorbidities
Gastroenteritis 3.5 0.6 5.9 3.3
URTI in previous 12 months 67.2 64.2 68.5 68.7
Hospitalization in previous 12 months(all causes) 14.1 16.0 14.4 11.5
Prescriptions on day of inclusion (at least one in each category as follows)
Antibiotic 32.6 39.4 41.4 13.3*
Antipyretic/anti-inflammatory drugs 40.5 52.1 45.8 20.7*
Homeopathic drug for URTI 21.6 0.6 9.4 61.3*
1Type of medical practice according to physicians’ prescribing preferences: GP-CM, conventional medicine; GP-Mx, mixed prescribing practice (conventional and
homeopathic); GP-Ho, registered homeopathic physicians.
*Difference statistically significant (p,0.05).
doi:10.1371/journal.pone.0089990.t003
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fever (37.3%), nasal obstruction (52.7%) and cough (64.0%) than
those consulting a GP-CM (53.3%, 63.0% and 76.4%, respec-
tively; all three statistically significant). Patients in the GP-Mx were
comparable to those in the GP-CM group.
Prescribing preferences of physicians in the three groups were
confirmed at baseline by their respective prescribing rates of
homeopathic drugs, which were 0.6%, 9.4% and 61.3%,
respectively, in the GP-CM, GP-Mx and GP-Ho groups
(Table 3). Conversely, antibiotic and antipyretic/anti-inflamma-
tory drug prescriptions, which were relatively comparable between
the GP-CM and the GP-Mx groups with rates above 40%, were
much lower in the GP-Ho group with rates at or below 20%.
Table 1 shows the multivariate analyses on drug utilization,
resolution of the URTI symptoms and occurrence of potentially
associated infections. For antibiotic and antipyretic/anti-inflam-
matory drug utilization, the lower consumption observed at
baseline in the GP-Ho group was maintained over the twelve-
month follow-up with an adjusted probability of patients’ reporting
significantly lower than the GP-CM group both for antibiotics
(OR=0.43; 95% CI: 0.27–0.68) and for antipyretic/anti-inflam-
matory drugs (OR=0.54; 95% CI: 0.38–0.76). There was no
difference in drug utilization between the groups GP-Mx and GP-
CM.
For resolution of the URTI symptoms at one-month follow-up,
patients declared similar improvement in the three groups (77.0%,
81.1% and 77.7% respectively in the GP-CM, GP-Mx and GP-Ho
groups) with no statistically significant differences in multivariate
analyses adjusting for baseline characteristics (OR=1.16; 95% CI:
0.64–2.10). On the other hand, there was a slightly higher rate of
potentially associated infections (otitis media/externa and sinusitis)
reported by patients in the GP-Ho group over twelve months
follow-up (17.7%) compared to the GP-CM group (16.9%), a
difference that was not statistically significant (OR=1.71; 95% CI:
0.90–3.20). Results on symptoms resolution and occurrence of
potentially associated infections exhibited wide confidence inter-
vals.
Discussion
This population-based prospective cohort study described and
compared clinical management and evolution of patients consult-
ing for URTI between three groups of physicians with different
levels of prescribing preferences for homeopathy. At baseline,
patients who chose to be seen by GP-Ho for URTI declared to
have used half the amount of antibiotics and antipyretic/anti-
inflammatory drugs compared to patients seen by conventional
medicine practitioners. This lower consumption of conventional
medications in the GP-Ho group was sustained over the 12-month
follow-up. At the same time, no difference in the resolution of the
URTI symptoms was observed between groups but confidence
intervals were wide indicating lack of statistical power for that
outcome. Similarly, the excess rate of potentially associated
infections observed in the GP-Ho group, although non-statistically
significant, cannot be ruled out. No difference was seen in patients
from the GP-Mx group, which was comparable to the GP-CM
group on all outcomes.
Previous observational studies conducted in several countries
have shown an antibiotic-sparing effect resulting from manage-
ment by GPs using homeopathy without increase in complication
rates of URTI [10,16]. Patients’ education, including appropriate
indication for antibiotic use, infection prognosis, and alternative
treatment recommendations, may contribute to lower patients’
expectations toward antibiotics while improving satisfaction [2].
This has been described in France during the 2009–2010 influenza
season [17]. Authors have pointed out the difficulty of sorting out
patients’ expectations/motivation and homeopathic care itself,
including their providers [18,19].
The rise in bacterial resistance to antibiotics is widely
recognized as a major threat to public health [6,20]. Antibiotic
prescribing for URTI varies widely within and across countries
[21,22] suggesting that further control of antibiotic prescribing is
possible. Many countries have implemented policies aimed at
reducing inappropriate prescribing of antimicrobials in primary
care [6,22]. In that context, our results are not unexpected and
can contribute to reinforce the motivation of decision makers to
pursue these policies [23–25].
Our results could be explained in part by the different
characteristics of patients seen by GPs who practice homeopathy
and by the lower rate of fever, nasal obstruction and cough in the
GP-Ho group at baseline compared to the two other groups.
Adjustment by severity of URTI and other potential confounders
did not alter the results but residual confounding cannot be
excluded. As for our observation of a small non-statistically
significant excess in the occurrence of potentially associated
infections in the GP-Ho group, it may be due to chance or to a
lack of protection against these infections. The latter instance
cannot be ruled out as the study lacked statistical power to
distinguish between the two interpretations.
Study limitations
The participation rate in this URTI cohort study was only
36.9% of eligible patients, which is comparatively equivalent to
what is seen in general health surveys where patients are asked to
participate in a long follow-up [26]. Given that this study was
appended to a general population health survey, contributed at
reducing the risk of selection bias of physicians and patients. The
overall prevalence of URTI in this survey (12.4%; 95% CI: 11.5–
13.2) was compatible with statistics on GP consultations in France
[11]. Precautions taken to calibrate the final sample so as to ensure
representatively of the eligible population contributed at reducing
sampling bias but without ruling it out entirely. The results may
also be subject to residual confounding because the propensity
score may have not accounted for all the differences between
patients who seek treatment from different types of physicians.
Another potential limitation is related to the nature of URTI
diagnoses that have not been validated against a disease
management guideline. No such attempt was made to preserve
the authenticity of primary care practice in real life. This is
partially why diagnoses of bronchitis and bronchiolitis were
included in this cohort as they may represent co-occurrences of
URTI. The standardized collection of symptoms allowed a partial
control for severity of URTI at inclusion. Two conditions, sinusitis
and otitis, were studied as proxies for the occurrence of infections
potentially associated to the URTI. Diagnoses were obtained from
patients’ self-declaration over the telephone and should not be
interpreted strictly. It is not known whether they represent true
complications or URTI and/or represent associated infections as a
result of no antibiotic treatment. This should be studied,
particularly in view of the apparent excess of infections observed
in the GP-Ho group. However, the lack of diagnostic confirmation
should not bias the comparison between the groups but may bias
the results toward the null and thus reducing the statistical
significance of the observation. In view of the different character-
istics of patients in the GP-Ho group at inclusion, the lower
frequency of symptoms reported that group might be explained by
a lower threshold of these patients to consult a physician rather
than a true difference in the diagnoses makeup of the group.
EPI3 Study on Homeopathy and Antibiotics for URTI
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Finally, results on resolution of URTI symptoms were
underpowered to show non-inferiority between groups as
illustrated by the wide confidence intervals. The estimates however
were close to unity in both GP-Mx and GP-Ho groups, indicating
similarity for self-declaration of symptoms resolution at one month
between patients from both groups. Sample size was sufficient to
show an Odds ratio superior to 1.22 (or inferior to 0.82) for the
main outcomes. Strengths of this study included the length of
follow-up and the quality of the data which combined medical and
patient information collected from physicians and patients. Drug
consumption was obtained from patients interviews using a
validated approach [13,14] that allowed the identification of
prescription drugs as well as those obtained over-the-counter or
from the family pharmacy, the latter being known to be an
important source of self-treatment for URTI [27].
In conclusion, this cohort study showed that patients with URTI
who choose to consult homeopathy-certified GPs in primary care,
had a lower consumption of antibiotics and antipyretic/anti-
inflammatory drugs as compared to patients seen by physicians
who use conventional medicine. This difference may be due to
specific attributes of either physicians or patients but also
interactions between the two. No difference was observed for
patients consulting GPs with mixed prescribing habits. The non-
significant excess of potentially associated infections in the GP-Ho
group esteemed through modelling may be due to chance alone or
driven by less use antibiotics. Further studies are needed to clarify
this effect. Other large studies are needed to establish the long-
term consequences of different prescribing practices in primary
care.
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